BOSTON, October 6, 2016 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the launch of its Active Tracking service. The service follows Good Distribution Practice (GDP) requirements by providing biopharmaceutical companies with near real-time temperature and location monitoring of investigational medicinal products (IMPs) from central distribution centre’s to clinical trial sites.
An increasing number of medicinal products require a temperature-controlled supply chain to maintain product integrity during transport, including approximately 75 percent of biological drugs, 10 to 15 percent of small molecule therapies, 100 percent of vaccines, and a large percent of biologic samples and diagnostic tools. Temperature deviations and shipment delays can impact patient safety, create patient retention issues, and cause additional manufacturing and shipment costs.
Supported by PAREXEL’s Clinical Trial Supply & Logistics global depot and service network, PAREXEL’s Active Tracking service utilises supply chain monitoring technology to detect incidents, such as shipment delays, shipment diversions, and temperature deviations. When combined with PAREXEL ClinPhone® RTSM interactive response technology (IRT), temperature and location data is automatically sent in near real-time to clinical trial sites for assessment. This integration his service cking service uses this infperature October 1, 2016.enables greater automated preventive or remedial actions, such asservice rmation tine or release,der temperature October 1, 2016.such assu release, quarantine, and automatic re-order of temperature-controlled products, simplifying temperature management for sites and sponsors.
“In the past, an investigational site had to wait until it received a shipment and downloaded the data from the temperature logger to find out if a drug’s temperature had been compromised,” said Sanjay Vyas, Corporate Vice President, Clinical Trial Supplies & Logistics, PAREXEL. “With PAREXEL’s Active Tracking service, we can monitor IMPs from packaging at our depots through transit to clinical trial sites, in near real-time. This innovation in clinical supply chain management allows us to quickly respond to any temperature complications, which can reduce safety risks for patients as well as manufacturing and shipment costs for clients.”
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 84 locations in 51 countries around the world, and had approximately 18,600 employees in the fourth quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.Editor's Details
Last updated on: 07/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.